Efficacy of live attenuated porcine reproductive and respiratory syndrome virus 2 strains to protect pigs from challenge with a heterologous Vietnamese PRRSV 2 field strain

被引:2
|
作者
Sattler, Tatjana [1 ,2 ]
Pikalo, Jutta [1 ]
Wodak, Eveline [1 ]
Revilla-Fernandez, Sandra [1 ]
Steinrigl, Adi [1 ]
Bago, Zoltan [1 ]
Entenfellner, Ferdinand [3 ]
Claude, Jean-Baptiste [4 ]
Pez, Floriane [4 ]
Francillette, Maela [4 ]
Schmoll, Friedrich [1 ]
机构
[1] AGES, Inst Vet Dis Control, Robert Koch Gasse 17, A-2340 Modling, Austria
[2] Univ Leipzig, Clin Ruminants & Swine, Tierkliniken 11, D-04103 Leipzig, Germany
[3] Vet Practice Entenfellner, Bonnleiten 8, A-3073 Stossing, Austria
[4] BioSellal, Batiment Accinov,317 Ave Jean Jaures, F-69007 Lyon, France
关键词
HP PRRSV 2; Vaccine; Efficacy; Viral replication; Immune response; UNITED-STATES; VACCINE; PATHOGENICITY; CHINA; ANTIBODIES;
D O I
10.1186/s12917-018-1451-y
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: Effective vaccines against porcine reproductive and respiratory syndrome virus (PRRSV), especially against highly pathogenic (HP) PRRSV are still missing. The objective of this study was to evaluate the protective efficacy of an experimental live attenuated PRRSV 2 vaccine, composed of two strains, against heterologous challenge with a Vietnamese HP PRRSV 2 field strain. For this reason, 20 PRRSV negative piglets were divided into two groups. The pigs of group 1 were vaccinated with the experimental vaccine, group 2 remained unvaccinated. All study piglets received an intranasal challenge of the HP PRRSV 2 on day 0 of the study (42 days after vaccination). Blood samples were taken on days 7 and 21 after vaccination and on several days after challenge. On day 28 after challenge, all piglets were euthanized and pathologically examined. Results: On days 7 and 21 after vaccination, a PRRSV 2 viraemia was seen in all piglets of group 1 which remained detectable in seven piglets up to 42 days after vaccination. On day 3 after challenge, all piglets from both groups were positive in PRRSV 2 RT-qPCR. From day 7 onwards, viral load and number of PRRSV 2 positive pigs were lower in group 1 than in group 2. All pigs of group 1 seroconverted after PRRSV 2 vaccination. PRRSV antibodies were detected in serum of all study pigs from both groups from day 14 after challenge onwards. In group 2, moderate respiratory symptoms with occasional coughing were seen following the challenge with HP PRRSV 2. Pigs of group 1 remained clinically unaffected. Interstitial pneumonia was found in four piglets of group 1 and in all ten piglets of group 2. Histopathological findings were more severe in group 2. Conclusions: It was thus concluded that the used PRRSV 2 live experimental vaccine provided protection from clinical disease and marked reduction of histopathological findings and viral load in pigs challenged with a Vietnamese HP PRRSV 2 field strain.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] The efficacy of a modified live virus vaccine Fostera® PRRS against heterologous strains of porcine reproductive and respiratory syndrome virus: A meta-analysis
    Rawal, G.
    Angulo, J.
    Linhares, D. C. L.
    Mah, C. K.
    Van Vlaenderen, I.
    Nautrup, B. Poulsen
    RESEARCH IN VETERINARY SCIENCE, 2022, 150 : 170 - 178
  • [32] Parameters of humoral and cellular immunity following vaccination of pigs with a European modified-live strain of porcine reproductive and respiratory syndrome virus (PRRSV)
    Sipos, W
    Duvigneau, C
    Pietschmann, P
    Höller, K
    Hartl, R
    Wahl, K
    Steinborn, R
    Gemeiner, M
    Willheim, M
    Schmoll, F
    VIRAL IMMUNOLOGY, 2003, 16 (03) : 335 - 346
  • [33] Reproductive performance of gilts following vaccination and subsequent heterologous challenge with European strains of porcine reproductive and respiratory syndrome virus
    Scortti, Mariela
    Prieto, Cinta
    Simarro, Isabel
    Castro, Jose M.
    THERIOGENOLOGY, 2006, 66 (08) : 1884 - 1893
  • [34] Vaccination of 1-day-old pigs with a porcine reproductive and respiratory syndrome virus (PRRSV) modified live attenuated virus vaccine is able to overcome maternal immunity
    Balasch, Monica
    Fort, Maria
    Taylor, Lucas P.
    Calvert, Jay G.
    PORCINE HEALTH MANAGEMENT, 2018, 4
  • [35] Vaccination of 1-day-old pigs with a porcine reproductive and respiratory syndrome virus (PRRSV) modified live attenuated virus vaccine is able to overcome maternal immunity
    Monica Balasch
    Maria Fort
    Lucas P. Taylor
    Jay G. Calvert
    Porcine Health Management, 4
  • [36] Effectiveness of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts
    Oh, Taehwan
    Kim, Hanjin
    Park, Kee Hwan
    Jeong, Jiwoon
    Kang, Ikjae
    Yang, Siyeon
    Chae, Chanhee
    CANADIAN JOURNAL OF VETERINARY RESEARCH-REVUE CANADIENNE DE RECHERCHE VETERINAIRE, 2019, 83 (04): : 248 - 254
  • [37] Replication characteristics of eight virulent and two attenuated genotype 1 and 2 porcine reproductive and respiratory syndrome virus (PRRSV) strains in nasal mucosa explants
    Frydas, Ilias S.
    Nauwynck, Hans J.
    VETERINARY MICROBIOLOGY, 2016, 182 : 156 - 162
  • [38] Vaccination of sows against type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) before artificial insemination protects against type 2 PRRSV challenge but does not protect against type 1 PRRSV challenge in late gestation
    Han, Kiwon
    Seo, Hwi Won
    Park, Changhoon
    Chae, Chanhee
    VETERINARY RESEARCH, 2014, 45
  • [39] Vaccination of sows against type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) before artificial insemination protects against type 2 PRRSV challenge but does not protect against type 1 PRRSV challenge in late gestation
    Kiwon Han
    Hwi Won Seo
    Changhoon Park
    Chanhee Chae
    Veterinary Research, 45
  • [40] Comparative Effects of Vaccination against Porcine Circovirus Type 2 (PCV2) and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in a PCV2-PRRSV Challenge Model
    Park, Changhoon
    Oh, Yeonsu
    Seo, Hwi Won
    Han, Kiwon
    Chae, Chanhee
    CLINICAL AND VACCINE IMMUNOLOGY, 2013, 20 (03) : 369 - 376